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0.009). Adjusted for community antibiotic prescribing,
the hospital costs of patients with LRTI were significantly
higher than those of patients with COAD (p = 0.001) but
not those of patients with COAD+ LRTI (p = 0.096).
CONCLUSION: Economic models of the potential impact
of different community antibiotics on hospital LRTI costs
will be subject to case mix bias unless they adjust for com-
munity antibiotic use and co-morbidity with COAD.
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The platinum chemotherapeutic compounds (cisplatin
and carboplatin) are widely used in the treatment of ad-
vanced Non-Small Cell Lung Cancer (NSCLC). The in-
troduction of new agents such as paclitaxel and vinorel-
bine has resulted in the development of combination
regimens with improved response rates and survival. Two
commonly used regimens, paclitaxellcarboplatin (TP) and
vinorelbine/cisplatin (NP), are compared in this pharma-
coeconomic analysis.
METHODS: A meta-analysis of available clinical trials
was conducted to estimate the clinical effectiveness of TP
and NP. Literature and physician interviews provided in-
formation on resource utilization and adverse event man-
agement (AEM) for these regimens. Treatment models
were populated with Medicare reimbursement figures to
compare the expected cost of treatment.
RESULTS: The expected cost of the TP and NP regimens
was $19,322 and $20,790, respectively. Although the ef-
ficacy of these regimens has not been compared in a ran-
domized trial, meta-analysis of regimented phase II and
III studies showed no statistically significant differences
in response rates. Therefore, equivalent efficacy is as-
sumed in this cost comparison. A 20% variation in the
cost of underlying resources yielded a 7% standard devia-
tion in results. This sensitivity analysis showed that the
costs of these regimens are insensitive to variations in un-
derlying parameters.
CONCLUSION: This study suggests that TP is the phar-
macoeconomic NSCLC treatment of choice when com-
pared to NP. The analysis reveals that low administration
and AEM costs are the key drivers in the lower treatment
cost of TP.
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